Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399427 | 0.90 | MAPKAPK5 (0.45) | GPR119MAPKAPK5USP30GSK3B | |
| SCHEMBL1685157 | 0.81 | MAPKAPK5 (0.46) | MAPKAPK5JAK2JAK1GSK3B | |
| SCHEMBL1685196 | 0.80 | MAPKAPK5 (0.51) | MAPKAPK5PIM1GSK3B | |
| SCHEMBL1685321 | 0.78 | MAPKAPK5 (0.53) | MAPKAPK5JAK2PIM1GSK3B | |
| SCHEMBL1685232 | 0.77 | MAPKAPK5 (0.51) | MAPKAPK5GSK3B | |
| SCHEMBL10134756 | 0.76 | MAPKAPK5 (0.53) | MAPKAPK5PIM1GSK3B | |
| SCHEMBL1685156 | 0.76 | MAPKAPK5 (0.51) | MAPKAPK5JAK2PIM1GSK3B | |
| SCHEMBL1685332 | 0.75 | MAPKAPK5 (0.51) | MAPKAPK5GSK3B | |
| SCHEMBL1685142 | 0.75 | MAPKAPK5 (0.46) | MAPKAPK5JAK2JAK1GSK3B | |
| SCHEMBL12618944 | 0.75 | MAPKAPK5 (0.53) | MAPKAPK5PIM1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | GPR119 1662/4885MAPKAPK5 19/4885BRD4 683/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | GPR119 1662/4885MAPKAPK5 19/4885BRD4 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.